Sialylated glycoprotein compositions and uses thereof
The present application relates to sialylated glycoprotein compositions and methods of their use in treating various conditions and disorders.
1. A composition comprising a recombinant glycoprotein, wherein the recombinant glycoprotein is human β-glucuronidase and has a sialylation content of at least 0.7 mol/mol of the recombinant glycoprotein.
2. The composition of claim 1 , wherein the recombinant glycoprotein has a high level of mannose-6-phosphate (M6P) moieties.
3. The composition of claim 1 , wherein the recombinant glycoprotein has a sialylation content of at least 1 mol/mol and a high level of M6P moieties of at least 10 mol % of the total glycan of the recombinant glycoprotein.
4. The composition of claim 1 , wherein the recombinant glycoprotein has a high level of M6P moieties and a M6P dependent half-maximum concentration of no more than 3 nM of the recombinant glycoprotein into human fibroblast cells.
5. A preparation of a population of a recombinant glycoprotein, wherein the recombinant protein is human β-glucuronidase and wherein at least 10% of the population of the recombinant glycoprotein is sialylated.
6. The preparation of claim 5 , wherein the recombinant protein has a sialylation content of at least 0.7 mol/mol of the recombinant protein.
7. The preparation of claim 5 , wherein the recombinant protein has a high level of M6P moieties.
8. The preparation of claim 5 , wherein the recombinant protein has a sialylation content of at least 1 mol/mol and a high level of M6P moieties of at least 10 mol % of the total glycan of the recombinant glycoprotein.
9. The preparation of claim 5 , wherein the recombinant glycoprotein has a high level of M6P moieties and an half-maximum uptake concentration of not more than 3 nM of the recombinant glycoprotein into human fibroblast cells.